Spartalizumab
Spartalizumab is an antibody pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against programmed cell death protein 1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
67 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Melanoma | D008545 | — | — | 7 | 6 | 1 | — | — | 12 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 4 | 4 | 1 | — | — | 7 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 16 | 9 | — | — | — | 18 |
| Non-small-cell lung carcinoma | D002289 | — | — | 10 | 5 | — | — | — | 14 |
| Triple negative breast neoplasms | D064726 | — | — | 10 | 5 | — | — | — | 13 |
| Carcinoma | D002277 | — | C80.0 | 8 | 8 | — | — | — | 13 |
| Colorectal neoplasms | D015179 | — | — | 9 | 2 | — | — | — | 11 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 4 | 2 | — | — | — | 6 |
| Renal cell carcinoma | D002292 | EFO_0000376 | — | 4 | 2 | — | — | — | 6 |
| Adenocarcinoma | D000230 | — | — | 2 | 4 | — | — | — | 6 |
| Lung neoplasms | D008175 | HP_0100526 | C34.90 | 3 | 2 | — | — | — | 5 |
| Hepatocellular carcinoma | D006528 | — | C22.0 | 4 | 3 | — | — | — | 5 |
Show 47 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 3 | — | — | — | — | 3 |
| Kidney neoplasms | D007680 | EFO_0003865 | C64 | 2 | — | — | — | — | 2 |
| Leukemia | D007938 | — | C95 | 1 | — | — | — | — | 1 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 1 | — | — | — | — | 1 |
| Hematologic diseases | D006402 | EFO_0005803 | D75.9 | 1 | — | — | — | — | 1 |
| Myeloid leukemia | D007951 | — | C92 | 1 | — | — | — | — | 1 |
| Myelomonocytic leukemia juvenile | D054429 | — | C93.3 | 1 | — | — | — | — | 1 |
| Preleukemia | D011289 | — | — | 1 | — | — | — | — | 1 |
| Bone marrow diseases | D001855 | — | — | 1 | — | — | — | — | 1 |
| Syndrome | D013577 | — | — | 1 | — | — | — | — | 1 |
Show 11 more
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Spartalizumab |
| INN | spartalizumab |
| Description | Spartalizumab (INN; development code PDR001) is a monoclonal antibody and checkpoint inhibitor that is being investigated for melanoma.
|
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL4297831 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | QOG25L6Z8Z (ChemIDplus, GSRS) |
Target
Agency Approved
PDCD1
PDCD1
Alternate
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,678 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
299 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use